The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:2157-2158 November 16, 2006 Number 20
NextNext

More on Life-Threatening Asthma and Salmeterol

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
To the Editor: Weinberger and Abu-Hasan (Aug. 24 issue)1 report severe asthma in two patients receiving inhaled corticosteroids and salmeterol. Each actuation of the salmeterol inhaler also delivers xinafoate, which according to the package insert has "no apparent pharmacological activity." However, at a molecular level, xinafoate is similar to compounds such as plicatic acid that are known to cause asthma.

Among the more than 250 known causes2 of occupational asthma are organic compounds of low molecular weight with bifunctional reactivity composed of at least two basic, hydroxyl, carboxyl, sulfonyl, isocyanate, or similar reactive groups.3 Xinafoate has a molecular mass of . . . [Full Text of this Article]


Related Letters:

Life-Threatening Asthma during Treatment with Salmeterol
Weinberger M., Abu-Hasan M.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:852-853, Aug 24, 2006. Correspondence


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.